Viva CT

Manufacturer: JayMac Pharmaceuticals LLC | Sancilio
Effective date: 2012-05-03
Label type: HUMAN PRESCRIPTION DRUG LABEL
Version: 1
Source: full-release
Hydrated at: 2026-05-31 20:15:11

Label at a glance#

ProductViva CT Prenatal

Active ingredientFOLIC ACID, FERROUS FUMARATE, ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL ACETATE, THIAMINE MONONITRATE, RIBOFLAVIN, PYRIDOXINE HYDROCHLORIDE, CYANOCOBALAMIN, ZINC OXIDE, CUPRIC SULFATE ANHYDROUS, Selenomethionine

Label structure14 sections

Indications and uses

Viva ® CT Prenatal Chewable is indicated for the distinct nutritional requirements of individuals in need of PRENATAL/POSTNATAL dietary supplementation as determined by a licensed medical practitioner. This product can be used fordietary management prior to conception. Viva ® CT Prenatal Chewable should be administered under the supervision of a licensed medical practitioner.

Dosage and administration

Chew and swallow one tablet daily, or as directed by a licensed medical practitioner.

Storage and handling

Store at Controlled Room Temperature 15°- 30°C (59°- 86°F). [See USP]. Dispense in a tight, light-resistant container.

Contacts and useful links#

PhoneLabel contact866-280-5961

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx Only

30ct round, light pink to pink-colored, fruit-flavored chewable tablets, embossed VCT

Prescription PRENATAL/POSTNATAL Vitamin

DESCRIPTION

DESCRIPTION SECTION

Viva^® CT Prenatal Chewable is an orally administered, chewable prescription PRENATAL/POSTNATAL vitamin specifically formulated for the dietary management of individuals with unique nutritional needs requiring increased folate levels. Viva^® CT Prenatal Chewable should be administered under the supervision of a licensed medical practitioner.

Each ROUND, LIGHT TO PINK-colored, chewable tablet contains the following dietary ingredients:

Folic Acid	1 mg^*
Iron (ferrous fumarate)	28 mg^*
Vitamin C (ascorbic acid)	100 mg^*
Vitamin D₃ (cholecalciferol)	400 IU^*
Vitamin E (acetate)	30 IU^*
Vitamin B₁ (thiamine mononitrate)	3 mg^*
Vitamin B₂ (riboflavin)	3 mg^*
Vitamin B₆ (pyridoxine HCl)	50 mg^*
Vitamin B₁₂ (cyanocobalamin)	15 mcg^*
Zinc (oxide)	20 mg^*
Copper (sulfate)	1 mg^*
L-(+)-Selenomethionine^†	50 mcg^*

* Daily Value not established for individuals with unique nutritional needs who are in need of nutritional supplementation as directed by a licensed medical practitioner.

† L-(+)-Selenomethionine as Selenium SeLECT^® is a registered trademark of Sabinsa Corporation, Piscataway, NJ. It has CAS #3211-76-5, and is chemically known as the diasterioisomerically pure (S)-(+)-2-Amino-4(methylseleno)-butanoic acid.

Other Ingredients

SPL UNCLASSIFIED SECTION

Xylitol, Microcrystalline Cellulose, Povidone, Magnesium Stearate, Talc, Fruit Punch Flavor, Sucralose.

FOLATE REGULATION

SPL UNCLASSIFIED SECTION

The term "folate" are B vitamins that include folic acid and any forms of active pteroylglutamates regardless of the reduction state of the molecule. Folates, or vitamin B9, are primarily hydrolyzed in the intestinal jejunum and the liver to the active circulating form of folate, I-methylfolate, with an intermediate stable form, 5,10-methylenetetrahydrofolate. Folic acid, including the reduced forms³ such as folinic acid, may obscure pernicious anemia above 0.1 mg doses, and must be administered under the supervision of a licensed medical practitioner.

The 1971, 1972, 1973, 1980, 1984, 2000, and 2010 Federal Register Notices addressed this concern while establishing that increased folate was proper therapy in megaloblastic anemias - specifically where homocysteine levels were elevated or risk of neural tube defects (NTDs) was at issue. The Federal Register Notice of August 2, 1973 (38 FR 20750) specifically states that: Dietary supplement preparations are available without a prescription (21 CFR 121.1134). Levels higher than dietary supplement amounts are available only with a prescription. Folic acid - including reduced forms, may be added to medical foods as defined in section 5(b) (3) of the Orphan Drug Act (21 USC 360ee(b)(3)), or to food (21 CFR 172.345).

3 This product is a dietary supplement that - due to increased folate levels (AUG 3 1973 FR 20750), requires an Rx on the label because of increased risk associated with masking of vitamin B₁₂ deficiency. As such, this product requires licensed medical supervision, an Rx status, and a National Drug Code (NDC) as required by pedigree reporting requirements.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Viva^® CT Prenatal Chewable is indicated for the distinct nutritional requirements of individuals in need of PRENATAL/POSTNATAL dietary supplementation as determined by a licensed medical practitioner. This product can be used fordietary management prior to conception. Viva^® CT Prenatal Chewable should be administered under the supervision of a licensed medical practitioner.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Viva^® CT Prenatal Chewable is contraindicated in individuals with a known hypersensitivity to any of the ingredients.

WARNINGS

WARNINGS SECTION

WARNING

BOXED WARNING SECTION

Accidental overdose of iron-containing products is the leading cause of poisoning of children under 6. KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.

PREGNANCY and NURSING MOTHERS

PREGNANCY SECTION

NURSING MOTHERS SECTION

Viva^® CT Prenatal Chewable is intended for use as a PRENATAL/POSTNATAL vitamin for lactating and non-lactating mothers. Talk with your medical practitioner to ensure adequate prenatal/postnatal supplementation. Consult with your licensed medical practitioner before using Viva^® CT Prenatal Chewable if pregnant or nursing.

PRECAUTIONS

PRECAUTIONS SECTION

Folate alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient. Folate in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.

PATIENT INFORMATION

INFORMATION FOR PATIENTS SECTION

Viva^® CT Prenatal Chewable is a prescription PRENATAL/POSTNATAL vitamin to be used only under licensed medical supervision.

DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

Drugs which may interact with folate include:

Antiepileptic drugs (AED): The AED class including, but not limited to, phenytoin, carbamazepine, primidone, valproic acid, fosphenytoin, valproate, phenobarbital and lamotrigine have been shown to impair folate absorption and increase the metabolism of circulating folate.
Additionally, concurrent use of folic acid has been associated with enhanced phenytoin metabolism, lowering the level of the AED in the blood and allowing breakthrough seizures to occur. Caution should be used when prescribing this product among individuals who are receiving treatment with phenytoin and other anticonvulsants.
Capecitabine: Folinic acid (5-formyltetrahydrofolate) may increase the toxicity of Capecitabine.
Cholestyramine: Reduces folic acid absorption and reduces serum folate levels.
Colestipol: Reduces folic acid absorption and reduces serum folate levels.
Cycloserine: Reduces folic acid absorption and reduces serum folate levels.
Dihydrofolate Reductase Inhibitors (DHFRI): DHFRIs block the conversion of folic acid to its active forms, and lower plasma and red blood cell folate levels. DHFRIs include aminopterin, methotrexate, pyrimethamine, triamterene, and trimethoprim.
Fluoxetine: Fluoxetine exerts a noncompetitive inhibition of the 5-methyltetrahydrofolate active transport in the intestine.
Isotretinoin: Reduced folate levels have occurred in some individuals taking isotretinoin.
L-dopa, triamterene, colchicine, and trimethoprim may decrease plasma folate levels.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs): NSAIDs have been shown to inhibit some folate dependent enzymes in laboratory experiments.
NSAIDs include ibuprofen, naproxen, indomethacin and sulindac.
Oral Contraceptives: Serum folate levels may be depressed by oral contraceptive therapy.
Methylprednisolone: Reduced serum folate levels have been noted after treatment with methylprednisolone.
Pancreatic Enzymes: Reduced folate levels have occurred in some individuals taking pancreatic extracts, such as pancreatin and pancrelipase.
Pentamidine: Reduced folate levels have been seen with prolonged intravenous pentamidine.
Pyrimethamine: High levels of folic acid may result in decreased serum levels of pyrimethamine.
Smoking and Alcohol: Reduced serum folate levels have been noted.
Sulfasalazine: Inhibits the absorption and metabolism of folic acid.
Metformin treatment in individuals with type 2 diabetes decreases serum folate.
Warfarin can produce significant impairment in folate status after a 6-month therapy.
Heme-iron: Can compete for transport and reduce folate absorption. Ensure adequate medical supervision to ensure proper iron levels.
Folinic acid may enhance the toxicity of fluorouracil.
Concurrent administration of chloramphenicol and folinic acid in folate-deficient patients may result in antagonism of the haematopoietic response to folate.
Caution should be exercised with the concomitant use of folinic acid and trimethoprim-sulfamethoxazole for the acute treatment of Pneumocystis carinii pneumonia in patients with HIV infection as it is associated with increased rates of treatment failure and mortality in a placebo controlled study.

**Folate is a broad term that includes folic acid and all reduced forms including I-methylfolate and folinic acid. Viva® CT Prenatal Chewable does not contain I-methylfolate or folinic acid but these warnings are included as general folate information.

Drugs which interact with vitamin B₆:

Vitamin B₆ should not be given to individuals receiving the drug levodopa because the action of levodopa is antagonized by vitamin B₆. However, vitamin B₆ may be used concurrently in individuals receiving a preparation containing both carbidopa and levodopa.

Drugs which may interact with vitamin B₁₂:

Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B₁₂.
Nitrous oxide can produce a functional vitamin B₁₂ deficiency.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Allergic sensitization has been reported following both oral and parenteral administration of folate. Paresthesia, somnolence, nausea, and headaches have been reported with vitamin B₆. Mild transient diarrhea, polycythemia vera, itching, transitory exanthema and the feeling of swelling of the entire body have been associated with vitamin B₁₂.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Chew and swallow one tablet daily, or as directed by a licensed medical practitioner.

STORAGE

STORAGE AND HANDLING SECTION

Store at Controlled Room Temperature 15°- 30°C (59°- 86°F). [See USP]. Dispense in a tight, light-resistant container.

HOW SUPPLIED

HOW SUPPLIED SECTION

Viva^® CT Prenatal Chewable is supplied as round, light pink to pink-colored chewable tablets embossed VCT, and are dispensed in bottles of 30 tablets.

NDC³ 64661-811-30

SPL UNCLASSIFIED SECTION

Call your medical practitioner about side effects. You may report side effects by calling 866-280-5961.

KEEP THIS OUT OF REACH OF CHILDREN.

Rx Only

All prescriptions using this product shall be pursuant to State statutes as applicable.

Manufactured by: Sancilio & Company, Inc.,
3874 Fiscal Court, Suite 200, Riviera Beach, FL 33404

JAYMAC
Pharmaceuticals, LLC

MADE IN CHINA

REV 4/2012

PRINCIPAL DISPLAY PANEL - 30 Chewable Tablet Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Rx
Patent Protected

30 ct. Fruit-flavored,
Chewable Tablets

Viva^®CT
Prenatal Chewable

Manufactured for:
JAYMAC
Pharmaceuticals, LLC

Sunset, LA 70584

Prescription Vitamin
NDC⁺⁺64661-811-30

PRINCIPAL DISPLAY PANEL - 30 Chewable Tablet Label

DailyMed Pharmacologic Classes#

Class, Version, Type table
Class	Version	Type	Effective
ASCORBIC ACID Pharmacologic Class Indexing	2	Indexing - Pharmacologic Class	20180813
CHOLECALCIFEROL Pharmacologic Class Indexing	2	Indexing - Pharmacologic Class	20180813
COPPER Pharmacologic Class Indexing	2	Indexing - Pharmacologic Class	20180813
CYANOCOBALAMIN Pharmacologic Class Indexing	2	Indexing - Pharmacologic Class	20180813
PYRIDOXINE Pharmacologic Class Indexing	1	Indexing - Pharmacologic Class	20170310

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
c599c4a0-705d-4ebb-ab1f-977af038f96a	Product name	1	20251124
59361619-24d9-b610-eca6-5a7f25ed5e03	Product name	5	20240909
b82b4008-22fd-05f5-6cc6-c0a6e81c65b8	Product name	2	20240805
910c1bd7-67d1-44c7-ad4f-9445f827edcc	Product name	1	20230808
91c62db0-0295-c81c-d10a-0856c259edd6	Product name	2	20200428
d32bc2b8-0bb7-2216-87aa-24639646e202	Product name	3	20190619
c5cd4727-ac49-4409-82b1-5bd8006c3ec7	Product name	1	20171122
d206bb34-ea65-399d-70d9-834f22dc2c18	Product name	3	20170724
5e18e798-5614-cf5c-0185-38b1cb77a093	Product name	2	20160822
60c52429-fcef-eb54-2387-43bc9e4f296b	Product name	1	20140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
64661-811-30	2020-01-31	C162847	48780-1	9d75b9d1-1af4-f424-e053-dadaa90a57ce	Viva ® CT Prenatal Chewable IRON SUPPLEMENT

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
64661-811-30	Viva CT Prenatal	30 in 1 BOTTLE	TABLET, CHEWABLE	30		1

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
64661-811	VIVA CT PRENATAL (FOLIC ACID, FERROUS FUMARATE, ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL ACETATE, THIAMINE MONONITRATE, RIBOFLAVIN, PYRIDOXINE HYDROCHLORIDE, CYANOCOBALAMIN, ZINC OXIDE, CUPRIC SULFATE ANHYDROUS, AND SELENOMETHIONINE) TABLET, CHEWABLE [JAYMAC PHARMACEUTICALS LLC]	1	Legacy NDC, 1 package rows	20120517_ad02306c-e1a3-441d-825e-d79047c61022.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
64661-811-30	EA - Each	64661-811	3e5abbd5-c2dd-45eb-8eb7-fa98494260d4	1	2013-02-13

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	SPL version
.ALPHA.-TOCOPHEROL ACETATE	ACTIVE INGREDIENT	9E8X80D2L0	1
ASCORBIC ACID	ACTIVE INGREDIENT	PQ6CK8PD0R	1
CHOLECALCIFEROL	ACTIVE INGREDIENT	1C6V77QF41	1
CUPRIC SULFATE ANHYDROUS	ACTIVE INGREDIENT	KUW2Q3U1VV	1
CYANOCOBALAMIN	ACTIVE INGREDIENT	P6YC3EG204	1
FERROUS FUMARATE	ACTIVE INGREDIENT	R5L488RY0Q	1
FOLIC ACID	ACTIVE INGREDIENT	935E97BOY8	1
PYRIDOXINE HYDROCHLORIDE	ACTIVE INGREDIENT	68Y4CF58BV	1
RIBOFLAVIN	ACTIVE INGREDIENT	TLM2976OFR	1
Selenomethionine	ACTIVE INGREDIENT	964MRK2PEL	1
THIAMINE MONONITRATE	ACTIVE INGREDIENT	8K0I04919X	1
ZINC OXIDE	ACTIVE INGREDIENT	SOI2LOH54Z	1
.ALPHA.-TOCOPHEROL	ACTIVE MOIETY	H4N855PNZ1	1
ASCORBIC ACID	ACTIVE MOIETY	PQ6CK8PD0R	1
CHOLECALCIFEROL	ACTIVE MOIETY	1C6V77QF41	1
COPPER	ACTIVE MOIETY	789U1901C5	1
CYANOCOBALAMIN	ACTIVE MOIETY	P6YC3EG204	1
FOLIC ACID	ACTIVE MOIETY	935E97BOY8	1
IRON	ACTIVE MOIETY	E1UOL152H7	1
PYRIDOXINE	ACTIVE MOIETY	KV2JZ1BI6Z	1
RIBOFLAVIN	ACTIVE MOIETY	TLM2976OFR	1
Selenomethionine	ACTIVE MOIETY	964MRK2PEL	1
THIAMINE	ACTIVE MOIETY	X66NSO3N35	1
ZINC OXIDE	ACTIVE MOIETY	SOI2LOH54Z	1
CELLULOSE, MICROCRYSTALLINE	INACTIVE INGREDIENT	OP1R32D61U	1
MAGNESIUM STEARATE	INACTIVE INGREDIENT	70097M6I30	1
POVIDONE	INACTIVE INGREDIENT	FZ989GH94E	1
SUCRALOSE	INACTIVE INGREDIENT	96K6UQ3ZD4	1
TALC	INACTIVE INGREDIENT	7SEV7J4R1U	1
XYLITOL	INACTIVE INGREDIENT	VCQ006KQ1E	1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 25 matching rows.

Viva CT Prenatal
FOLIC ACID, FERROUS FUMARATE, ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL ACETATE, THIAMINE MONONITRATE, RIBOFLAVIN, PYRIDOXINE HYDROCHLORIDE, CYANOCOBALAMIN, ZINC OXIDE, CUPRIC SULFATE ANHYDROUS, and Selenomethionine
FOLIC ACID
FERROUS FUMARATE
IRON
ASCORBIC ACID
CHOLECALCIFEROL
.ALPHA.-TOCOPHEROL ACETATE
.ALPHA.-TOCOPHEROL
THIAMINE MONONITRATE
THIAMINE
RIBOFLAVIN
PYRIDOXINE HYDROCHLORIDE
PYRIDOXINE
CYANOCOBALAMIN
ZINC OXIDE
CUPRIC SULFATE ANHYDROUS
COPPER
Selenomethionine
XYLITOL
CELLULOSE, MICROCRYSTALLINE
POVIDONE
MAGNESIUM STEARATE
TALC
SUCRALOSE

NDC Codes#

Product NDC, Package NDC table
Product NDC	Package NDC
64661-811	64661-811-30

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 18 matching rows.

Name, UNII, Kind table
Name	UNII	Kind
FOLIC ACID	935E97BOY8	ACTIB
FERROUS FUMARATE	R5L488RY0Q	ACTIB
ASCORBIC ACID	PQ6CK8PD0R	ACTIB
CHOLECALCIFEROL	1C6V77QF41	ACTIB
.ALPHA.-TOCOPHEROL ACETATE	9E8X80D2L0	ACTIB
THIAMINE MONONITRATE	8K0I04919X	ACTIB
RIBOFLAVIN	TLM2976OFR	ACTIB
PYRIDOXINE HYDROCHLORIDE	68Y4CF58BV	ACTIB
CYANOCOBALAMIN	P6YC3EG204	ACTIB
ZINC OXIDE	SOI2LOH54Z	ACTIB
CUPRIC SULFATE ANHYDROUS	KUW2Q3U1VV	ACTIB
Selenomethionine	964MRK2PEL	ACTIB
XYLITOL	VCQ006KQ1E	IACT
CELLULOSE, MICROCRYSTALLINE	OP1R32D61U	IACT
POVIDONE	FZ989GH94E	IACT
MAGNESIUM STEARATE	70097M6I30	IACT
TALC	7SEV7J4R1U	IACT
SUCRALOSE	96K6UQ3ZD4	IACT

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 3 · 166 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredient	IID ingredient	UNII	Dosage form / route	Potency	Maximum daily exposure	Match
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	TABLET, DELAYED RELEASE / ORAL		2210 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	TABLET / ORAL	15.04 mg		Exact identifier — unii candidate 12 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL		47 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	TABLET, CHEWABLE, EXTENDED RELEASE / ORAL		9 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	POWDER, FOR SUSPENSION / ORAL	4223 mg		Exact identifier — unii candidate 12 equally ranked IID candidates
TALC	TALC	7SEV7J4R1U	PELLET / ORAL		69 mg	Exact identifier — unii candidate 35 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	TABLET, CHEWABLE, EXTENDED RELEASE / ORAL		144 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
TALC	TALC	7SEV7J4R1U	CAPSULE / ORAL		729 mg	Exact identifier — unii candidate 35 equally ranked IID candidates
POVIDONE	POVIDONE	FZ989GH94E	SUSPENSION / ORAL	20 mg/5ml		Exact identifier — unii candidate 30 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	TABLET, SUGAR COATED / ORAL	NA		Exact identifier — unii candidate 39 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	WAFER / ORAL	66 mg		Exact identifier — unii candidate 39 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	PASTE / ORAL		180 mg	Exact identifier — unii candidate 12 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	IMPLANT / SUBCUTANEOUS	0.5 mg		Exact identifier — unii candidate 39 equally ranked IID candidates
TALC	TALC	7SEV7J4R1U	TABLET, FOR SUSPENSION / ORAL		24 mg	Exact identifier — unii candidate 35 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	TABLET, CHEWABLE / ORAL		127 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
SUCRALOSE	SUCRALOSE	96K6UQ3ZD4	GRANULE / ORAL	5.4 mg		Exact identifier — unii candidate 22 equally ranked IID candidates
TALC	TALC	7SEV7J4R1U	TABLET, EXTENDED RELEASE / ORAL		300 mg	Exact identifier — unii candidate 35 equally ranked IID candidates
POVIDONE	POVIDONE	FZ989GH94E	TROCHE / ORAL	30 mg		Exact identifier — unii candidate 30 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	SUSPENSION, EXTENDED RELEASE / ORAL		1120 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
POVIDONE	POVIDONE	FZ989GH94E	CAPSULE, COATED PELLETS / ORAL	10.03 mg		Exact identifier — unii candidate 30 equally ranked IID candidates
TALC	TALC	7SEV7J4R1U	TABLET, FILM COATED, EXTENDED RELEASE / ORAL		60 mg	Exact identifier — unii candidate 35 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	RING / VAGINAL		2 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	TABLET, EXTENDED RELEASE / ORAL		2752 mg	Exact identifier — unii candidate 12 equally ranked IID candidates
POVIDONE	POVIDONE	FZ989GH94E	INJECTION / INTRAMUSCULAR	0.2 %w/v		Exact identifier — unii candidate 30 equally ranked IID candidates
TALC	TALC	7SEV7J4R1U	TABLET, CHEWABLE, EXTENDED RELEASE / ORAL		18 mg	Exact identifier — unii candidate 35 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL		1576 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
POVIDONE	POVIDONE	FZ989GH94E	CAPSULE, DELAYED RELEASE PELLETS / ORAL		32 mg	Exact identifier — unii candidate 30 equally ranked IID candidates
POVIDONE	POVIDONE	FZ989GH94E	CAPSULE / ORAL		300 mg	Exact identifier — unii candidate 30 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	IMPLANT / INTRAVITREAL	1.66 mg		Exact identifier — unii candidate 28 equally ranked IID candidates
TALC	TALC	7SEV7J4R1U	GUM, CHEWING / BUCCAL	NA		Exact identifier — unii candidate 35 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	SOLUTION / ORAL		21600 mg	Exact identifier — unii candidate 12 equally ranked IID candidates
TALC	TALC	7SEV7J4R1U	GRANULE, DELAYED RELEASE / ORAL		525 mg	Exact identifier — unii candidate 35 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	LOZENGE / TRANSMUCOSAL		100 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
TALC	TALC	7SEV7J4R1U	CAPSULE, COATED PELLETS / ORAL	14 mg		Exact identifier — unii candidate 35 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	TABLET / SUBLINGUAL	43.2 mg		Exact identifier — unii candidate 28 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	TABLET, ORALLY DISINTEGRATING / ORAL		1800 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
POVIDONE	POVIDONE	FZ989GH94E	TABLET, EXTENDED RELEASE / ORAL		101 mg	Exact identifier — unii candidate 30 equally ranked IID candidates
POVIDONE	POVIDONE	FZ989GH94E	IMPLANT / SUBCUTANEOUS	6 mg		Exact identifier — unii candidate 30 equally ranked IID candidates
SUCRALOSE	SUCRALOSE	96K6UQ3ZD4	SPRAY, METERED / NASAL		2 mg	Exact identifier — unii candidate 22 equally ranked IID candidates
TALC	TALC	7SEV7J4R1U	TABLET / RECTAL	32.4 mg		Exact identifier — unii candidate 35 equally ranked IID candidates
SUCRALOSE	SUCRALOSE	96K6UQ3ZD4	GUM, CHEWING / BUCCAL		70 mg	Exact identifier — unii candidate 22 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	LOZENGE / ORAL		420 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	TABLET, FOR SUSPENSION / ORAL		131 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
POVIDONE	POVIDONE	FZ989GH94E	TABLET, DELAYED RELEASE / ORAL		53 mg	Exact identifier — unii candidate 30 equally ranked IID candidates
SUCRALOSE	SUCRALOSE	96K6UQ3ZD4	TABLET, EFFERVESCENT / ORAL		1080 mg	Exact identifier — unii candidate 22 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	TABLET, EXTENDED RELEASE / ORAL		5119 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	TABLET, COATED / ORAL		920 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	CAPSULE / ORAL		2169 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
TALC	TALC	7SEV7J4R1U	TABLET, DELAYED RELEASE PARTICLES / ORAL		56 mg	Exact identifier — unii candidate 35 equally ranked IID candidates
SUCRALOSE	SUCRALOSE	96K6UQ3ZD4	TABLET, EXTENDED RELEASE / ORAL		1 mg	Exact identifier — unii candidate 22 equally ranked IID candidates
TALC	TALC	7SEV7J4R1U	CAPSULE, EXTENDED RELEASE / ORAL		5119 mg	Exact identifier — unii candidate 35 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	GRANULE / ORAL		629 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	CAPSULE, EXTENDED RELEASE / ORAL		117 mg	Exact identifier — unii candidate 39 equally ranked IID candidates
MAGNESIUM STEARATE	MAGNESIUM STEARATE	70097M6I30	DROPS / ORAL	NA		Exact identifier — unii candidate 39 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	POWDER, FOR SOLUTION / ORAL		690 mg	Exact identifier — unii candidate 28 equally ranked IID candidates
TALC	TALC	7SEV7J4R1U	TABLET, ORALLY DISINTEGRATING / ORAL		80 mg	Exact identifier — unii candidate 35 equally ranked IID candidates
SUCRALOSE	SUCRALOSE	96K6UQ3ZD4	SUSPENSION, EXTENDED RELEASE / ORAL		16 mg	Exact identifier — unii candidate 22 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINE	MICROCRYSTALLINE CELLULOSE	OP1R32D61U	GRANULE, DELAYED RELEASE / ORAL	789.6 mg		Exact identifier — unii candidate 28 equally ranked IID candidates
SUCRALOSE	SUCRALOSE	96K6UQ3ZD4	TABLET, CHEWABLE / ORAL		28 mg	Exact identifier — unii candidate 22 equally ranked IID candidates
TALC	TALC	7SEV7J4R1U	TABLET / ORAL	1000 mg		Exact identifier — unii candidate 35 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
b55156d3-2850-423a-ab3e-f6db662afbdc			ad02306c-e1a3-441d-825e-d79047c61022	2012-05-03	Boxed warning, Warnings, Adverse reactions	Exact identifier spl id: b55156d3-2850-423a-ab3e-f6db662afbdc spl set id: ad02306c-e1a3-441d-825e-d79047c61022

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.